Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study

Recombinant LH Study Group, J N Hugues, J Soussis, I Calderon, J Balasch, R A Anderson, A Romeu

Research output: Contribution to journalArticlepeer-review

Abstract

In anovulatory women undergoing ovulation induction, addition of recombinant human LH (rLH) to FSH treatment may promote the dominance of a leading follicle when administered in the late follicular phase. The objective of this study was to find the optimal dose of rLH that can maintain the growth of a dominant follicle, whilst causing atresia of secondary follicles.
Original languageEnglish
Pages (from-to)629-35
Number of pages7
JournalHuman Reproduction
Volume20
Issue number3
DOIs
Publication statusPublished - 2005

Fingerprint

Dive into the research topics of 'Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study'. Together they form a unique fingerprint.

Cite this